Central Nervous System/ CNS

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 15:59:09 +0000

Summary

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietar...

$2,000.00

Amyotrophic Lateral Sclerosis (Central Nervous System) - Drugs in Development, 2021

Tue, 12 Oct 2021 15:07:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2021, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Health...

$2,500.00

Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021

Tue, 12 Oct 2021 15:07:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Drugs In Development, 2021, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central...

$2,000.00

Central Nervous System Lymphoma - Pipeline Insight, 2021

Wed, 08 Sep 2021 15:57:35 +0000

DelveInsight’s, “Central Nervous System Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Central Nervous System Lymphoma Understanding Central Nervous System Lymphoma: Overview Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Central nervous system lymphoma is more common in men than women. the exact causes of CNS lymphoma are not known, there are several factors that may increase a person's risk for developing the disease, such as having a com...

$1,500.00

Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Smoking Cessation, and Others), Product (Software and Devices)

Wed, 03 Apr 2019 10:44:28 +0000

The global digital therapeutics market was valued at $1,751 million in 2017 and is expected to reach $7,833 million by 2025, registering a CAGR of 20.5% during the forecast period. Digital therapeutics is a type of treatment option, which utilizes online health technologies and digital devices to treat numerous medical conditions and help maintain health discipline. Increase in adoption of smartphones & tablets coupled with rise in utilization of healthcare apps is the major factor that drives the growth of the global digital therapeutics market. In addition, increasing need to control healthcare costs supplements the market growth. However, lack of awareness regarding the availability of smartphone applications, especially in the developing countries, acts a major deterrent to the market growth. Conversely, high growth potential in the developing markets is expected to offer significant opportunities for the players operating in this market. The global digital therapeutics market is segmented into application, product, sales channel, and region. Based on application, the market ...

$5,370.00

Trigeminal Neuralgia (Tic Douloureux) - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2019, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide cove...

$2,000.00

Diabetic Neuropathy - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete rese...

$2,000.00

Neuropathic Pain - Pipeline Review, H1 2018

Mon, 03 Sep 2018 14:10:02 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibers could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under developm...

$2,000.00

Central Nervous System Disorder Drugs Markets in China

Wed, 09 May 2018 11:25:43 +0000

China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases....

$4,000.00

Central Nervous System Disorder Drugs Industry Forecasts - China Focus

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering f...

$1,800.00

Central Nervous System Disorder Drugs Companies in China

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Central Nervous System Disorder Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the ...

$1,800.00

Neuropathic Pain - Pipeline Review, H2 2017

Thu, 18 Jan 2018 15:45:29 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under develop...

$2,000.00

Neuropathic Pain - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

...

$4,950.00

Postherpetic Neuralgia- Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Postherpetic Neuralgia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Postherpetic Neuralgia forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Postherpetic Neuralgia till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Postherpetic Neuralgia market. • Identifying patient populations in the global “Postherpetic Neuralgia market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Postherpetic Neuralgia in each of the...

$4,950.00

Epiomic Epidemiology Series: Brain & CNS Cancer Forecast in 19 Major Markets 2016-2026

Thu, 06 Oct 2016 11:26:22 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Brain & CNS Cancer in 19 Major Markets Primary brain and central nervous system (CNS) tumours (ICD-10 codes C70-C72) are a group of primary tumours arising in the brain, meninges or central nervous system. As such, this is a cluster of conditions rather than one disease per se. There are considered to be over 120 types of brain tumour including glioblastoma multiforme (GBM), meningiomas and astrocytomas. This report provides the current incident population for Brain & CNS Cancer across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Turkey, Russia, India, Canada, Australia, Japan, China, South Korea, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbid...

$6,400.00

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprieta...

$2,000.00

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries...

$2,000.00

Peripheral Neuropathic Pain Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Peripheral Neuropathic Pain Global Clinical Trials Review, H2, 2016" provides an overview of Peripheral Neuropathic Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral Neuropathic Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective co...

$2,500.00

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Trigeminal Neuralgia Global Clinical Trials Review, H2, 2016" provides an overview of Trigeminal Neuralgia clinical trials scenario. This report provides top line data relating to the clinical trials on Trigeminal Neuralgia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to g...

$2,500.00

Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes

Thu, 15 Sep 2016 20:01:35 +0000

Summary

Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a disease, rather than just as a symptom of a primary cause. In the US, pain affects more people than cancer, diabetes and heart disease combined, with an estimated 100 million people having experienced at least one chronic pain episode in the last 12 months, at an annual cost of around $600 billion in medical treatment and lost productivity.

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action.

Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse-resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (...

$6,995.00

Peripheral Neuropathic Pain - Pipeline Review, H1 2016

Tue, 31 May 2016 09:45:03 +0000

Summary

Global Markets Direct’s, ‘Peripheral Neuropathic Pain - Pipeline Review, H1 2016’, provides an overview of the Peripheral Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial re...

$2,000.00

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016

Sun, 29 May 2016 12:24:04 +0000

Summary

Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy - Pipeline Review, H1 2016’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clini...

$2,000.00

Epiomic Epidemiology Series: Systemic Lupus Erythematosus Forecast in 8 Major Markets 2016-2026

Thu, 17 Mar 2016 11:02:03 +0000

Summary Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Systemic Lupus Erythematosus in 8 Major Markets Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterised by an autoantibody response to nuclear and cytoplasmic antigens. It is a systemic disease, with a large spectrum of signs and symptoms. It is a chronic condition that follows a relapsing and remitting course of its associated manifestations. It can affect the functions and appearance of skin, joints, kidneys, brain, the body’s blood cells and other organs. This report provides the current prevalent population for SLE across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of SLE have been quantified and pres...

$6,400.00

Epiomic Epidemiology Series: Neuropathic Pain Forecast in 15 Major Markets 2016-2026

Thu, 04 Feb 2016 12:47:18 +0000

Summary Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Neuropathic Pain in 15 Major Markets Neuropathic pain is generally defined as chronic pain resulting from injury to the nervous system. Neuropathic pain is caused by other conditions or diseases such as diabetes or herpes zoster infection, and is often accompanied by depression, sleep disturbances and fear/anxiety. Nerve fibres may be damaged or dysfunctional, causing incorrect signals to other pain centres. This report provides the current prevalent population for Neuropathic Pain across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Netherlands, Australia, Canada and Poland) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Neuropathic Pain have be...

$6,400.00